• Up to US$ 200 million available to help lower-income countries to quickly respond to pandemic; US$ 29 million approved as first tranche of funds to protect health workers and boost surveillance, testing

  • More than 21,500 cases and 681 deaths have been officially reported in 66 lower-income countries; true numbers likely to be much higher

  • Seth Berkley: “Health systems across the developing world face their biggest test in living memory, and Gavi is helping them to meet it”

Geneva, 9 April 2020 – Gavi, the Vaccine Alliance, will provide US$ 29 million in urgent initial funding to 13 lower-income countries to support their response to COVID-19, helping them to protect health care workers with personal protective equipment (PPE), perform vital surveillance and training, and fund diagnostic tests. There are further requests or interest from 21 countries, meaning more support from a total of up to US$ 200 million is likely to be approved in the coming days and weeks. This early funding is designed to provide immediate support until more substantial support from other sources is unlocked.

Gavi's response to pandemic

Tweet this infographic

The immunisation infrastructure that Gavi has helped build over the past two decades is also being used to help fight the pandemic. Across the world, staff in Ministries of Health and partner organisations trained and funded with Gavi support are now forming part of the COVID-19 response effort. In Karachi, Pakistan, technology funded by Gavi to monitor immunisation is now being used to monitor and track COVID-19 cases. 

So far, more than 21,500 cases and 681 deaths from COVID-19 have been officially reported in 66 Gavi-supported lower-income countries, however with low availability of testing the true number is likely to be much higher. India, Pakistan and Indonesia have reported the largest number of cases, and the spread of the virus is beginning to be reported in sub-Saharan Africa, where the number of countries reporting cases jumped from 5 to more than 30 in less than a week.

A Gavi analysis of Imperial College modelling suggests that, without any mitigation strategies, COVID-19 could lead to 12.9 million deaths in the 73 lowest-income countries, while a UNDP study suggests that income losses in developing countries could exceed US$ 220 billion.

“Health systems across the developing world face their biggest test in living memory, and Gavi is helping them to meet it,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “We are urgently offering vital funding and resources to help countries respond and protect the heroic health workers who will be the front line against this pandemic. Our support goes further than immediate funding: we have spent 20 years helping to strengthen the health systems, recruit and train the health workers, and improve the infrastructure that will now be more important than ever. This work will continue as we stand side by side with countries to both battle COVID-19 and keep immunisation programmes running. This infrastructure will also be critical to the roll-out of eventual COVID-19 vaccines.”

In March, the Gavi Board agreed to make available up to US$ 200 million of its funding for health systems to help countries respond to the COVID-19 pandemic. Gavi is considering further extending its array of support beyond the immediate response to help countries recover more quickly. 

The following 13 countries have had applications approved in record time, with the process of gathering applications and doing detailed due diligence to ensure the funding is directed to where it can make the biggest difference taking place in a matter of weeks. Seven further applications are under review. Gavi has also agreed to extend grants to Vietnam, which were set to end in June 2020, until the end of the year.

  • Myanmar: US$ 7.4 million approved for personal protective equipment (PPE) for health workers, disease surveillance, laboratory readiness, community engagement, risk communication and emergency response coordination.
  • Democratic Republic of Congo (DRC): US$ 6 million approved for logistics, infection prevention and control, emergency response coordination, risk communication and community engagement.
  • Ethiopia: US$ 5 million approved for infection control supplies, including personal protective equipment (PPE) for health workers, risk and behavioural communication, and community and civil society engagement.
  • Malawi: US$ 4.9 million approved for immediate infection prevention efforts, including protection of health workers, as well as strengthening emergency response coordination, screening and diagnostic efforts.
  • Afghanistan: US$ 2.1 million approved for diagnostic capacity, infection prevention and control, and hygiene, infection and laboratory supplies.
  • Sudan: US$ 1.3 million approved for hygiene and infection control training for health workers, infection control supplies, surveillance activities, support for the establishment of isolation centers and supervision activities.
  • Zimbabwe: US$ 1 million approved for test kits and personal protective equipment (PPE) for health workers.
  • South Sudan: US$ 720,000 approved for personal protective equipment (PPE) for health workers, surveillance, training, contact tracing, rapid response teams, infection prevention and control, and case management.
  • Timor-Leste: US$ 125,000 approved for training, operational costs and transportation.
  • Guinea-Bissau: US$ 70,000 approved for communications, surveillance, supervision, infection control and training.
  • Tajikistan: US$ 60,000 approved for social mobilisation and communication.
  • Bhutan: US$ 50,000 approved for procurement of supplies, training of student nurses, monitoring and demand generation.
  • Liberia: US$ 25,000 approved for communication to help counter rumours that routine vaccines are causing COVID-19.

Gavi has also been working with UNICEF Supply Division, the World Health Organization (WHO) and other partners to mitigate risks of vaccine supply disruption due to current transport restrictions. As a result, no programmatic interruptions have been reported to date due to transport issues; however, vaccine programmes across Gavi countries continue to be severely impacted due to other COVID-19-related issues.

Notes to editors

About Gavi, the Vaccine Alliance

Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world’s children against some of the world’s deadliest diseases. Since its inception in 2000, Gavi has helped to immunise a whole generation – over 760 million children – and prevented more than 13 million deaths, helping to halve child mortality in 73 developing countries. Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningitis and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation and reaching the unvaccinated children still being left behind, employing innovative finance and the latest technology – from drones to biometrics – to save millions more lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency. Learn more at www.gavi.org and connect with us on Facebook and Twitter.

The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation and other private sector partners. View the full list of donor governments and other leading organizations that fund Gavi’s work here.

Media Contacts

James Fulker, Media Manager
Mob: +41 79 429 55 05
Email: jfulker@gavi.org

COVID-19 related

View all

How long after I get COVID-19 will I test negative?

Testing positive for COVID-19 – even without symptoms – can be disruptive to daily life, but how long should we expect to test positive for?

First published on 29 October 2021, updated on 13 September 2022

Call for Applications: COVAX seeks experts for independent group on evidence-based vaccine decision-making

The COVAX Facility is seeking expressions of interest from the subject matter experts to join the COVAX Independent Product Group. The Independent Product Group (“IPG”) is established to provide scientific advice on COVID-19 vaccines and…

Q&A: Science ‘needs to listen to African voices’

Public speaking a lifelong skill for scientists. Drive behind research should come from grassroots. Science and art merge together in field of communication.

How did Kenya surpass its 2021 COVID-19 vaccination target?

Kenya was aiming to reach 10 million people with COVID-19 vaccines by the end of December 2021. Thanks to a clear strategy, COVAX support and the hard work of thousands of health workers, they reached their target.

Could mRNA vaccines protect against HIV?

Moderna has begun a trial with an experimental HIV vaccine based on the same technology underpinning its COVID-19 vaccine.

What’s the best way to tackle COVID and climate change? Anthropology, says the woman who predicted the global financial crisis

Financial Times journalist and author Gillian Tett discusses her new book, Anthro-Vision: How Anthropology Can Explain Business and Life.

Subscribe to our newsletter